GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis

被引：0

作者：

Poordad, Fred ^{[1
]}

Sedghi, Shahriar ^{[2
]}

Pockros, Paul J. ^{[12
]}

Ravendhran, Natarajan ^{[3
]}

Reindollar, Robert ^{[4
]}

Lucey, Michael R. ^{[5
]}

Epstein, Michael S. ^{[6
]}

Bank, Leslie ^{[7
]}

Bernstein, David E. ^{[8
]}

Trinh, Roger ^{[9
]}

Krishnan, Preethi ^{[9
]}

Pilot-Matias, Tami ^{[9
]}

Polepally, Akshanth R. ^{[9
]}

Pothacamury, Rajvineeth K. ^{[9
]}

Unnebrink, Kristina ^{[10
]}

Martinez, Marisol ^{[9
]}

Nelson, David R. ^{[11
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[2] Mercer Univ, Sch Med, Med & Surg, Macon, GA 31207 USA

[3] Digest Dis Associates, Baltimore, MD USA

[4] Piedmont Healthcare Carolinas Ctr Liver Dis, Statesville, NC USA

[5] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Div Gastroenterol Hepatol, Madison, WI USA

[6] Digest Disorders Associates, Anne Arundel Med Ctr, Annapolis, MD USA

[7] Reg Clin Res Inc, Endwell, NY USA

[8] Hofstra Northwell Sch Med, Manhasset, NY USA

[9] AbbVie Inc, N Chicago, IL USA

[10] AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany

[11] Univ Florida, Dept Med, Gainesvillle, FL USA

[12] Scripps Clin, Div Gastroenterol Hepatol, La Jolla, CA 92037 USA

来源：

HEPATOLOGY | 2016年 / 64卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

872

引用

页码：431A / 432A

页数：2

共 50 条

[21] Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis
Lawitz, Eric
Makara, Mihaly
Akarca, Ulus Salih
Thuluvath, Paul J.
Preotescu, Li Liana Lucia
Varunok, Peter
Morillas, Rosa Ma.
Hall, Coleen
Mobashery, Niloufar
Redman, Rebecca
Pilot-Matias, Tami
Vilchez, Regis A.
Hezode, Christophe
GASTROENTEROLOGY, 2015, 149 (04) : 971 - U678
[22] Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
Grebely, Jason
Puoti, Massimo
Wedemeyer, Heiner
Cooper, Curtis
Sulkowski, Mark S.
Foster, Graham R.
Berg, Thomas
Villa, Erica
Rodriguez-Perez, Federico
Wyles, David L.
Schnell, Gretja
Alami, Negar N.
Zhang, Zhenzhen
Dumas, Emily
Dore, Gregory J.
OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (11):
[23] Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia
Shafie, Asrul Akmal
Abu Hassan, Muhammad Radzi
Ong, Siew Chin
Virabhak, Suchin
Gonzalez, Yuri Sanchez
VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 164 - 171
[24] Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65years with HCV genotype 1 cirrhosis
Ascione, Antonio
De Luca, Massimo
Melazzini, Mario
Montilla, Simona
Trotta, Maria Paola
Petta, Salvatore
Puoti, Massimo
Sangiovanni, Vincenzo
Messina, Vincenzo
Bruno, Savino
Izzi, Antonio
Villa, Erica
Aghemo, Alessio
Zignego, Anna Linda
Orlandini, Alessandra
Fontanella, Luca
Gasbarrini, Antonio
Marzioni, Marco
Giannini, Edoardo G.
Craxi, Antonio
INFECTION, 2018, 46 (05) : 607 - 615
[25] The Efficacy of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir with or without Ribavirin in Patients with Hepatitis C Undergoing Chronic Haemodialysis: A Single Center Experience
Danis, Nilay
Pullukcu, Husnu
Yamazhan, Tansu
Ersoz, Galip
Unal, Nalan
Gunsar, Fulya
Turan, Ilker
Karasu, Zeki
Akarca, Ulus Salih
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2019, 25 (03): : 109 - 112
[26] EFFECTIVENESS AND SAFETY OF OMBITASVIR, PARITAPREVIR, RITONAVIR AND DASABUVIR PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS FROM THE SPANISH REALWORLD COHORT
Calleja, J. L.
Rincon, D.
Ruiz-Antoran, B.
Sacristan, B.
Perello, C.
Lens, S.
Fernanadez, I.
Gea, F.
Morillas, R. M.
Cabezas, J.
Pascasio, J. M.
Prieto, M.
Turnes, J.
Serra, M. A.
Arenas, J.
Torras, X.
Bonet, L.
Fernandez, C.
Samaniego, J.
Hernandez-Albujar, A.
Ampuero, J.
Moreno, J. M.
Saez-Royuela, F.
Alvarez-Navascues, C.
Diago, M.
Sanchez-Antolin, G.
de la Vega, J.
Sanchez-Ruano, J. J.
Andrade, R.
Butti, M.
Carrion, J. A.
Molina, E.
Simon, M. A.
Salcines, J. R.
Jorquera, F.
Montoliu, S.
Ahumada, A.
Hernaez, T.
Crespo, J.
JOURNAL OF HEPATOLOGY, 2016, 64 : S218 - S219
[27] Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir and dasabuvir combination with or without ribavirin in difficult-to-treat genotype 1 chronic hepatitis C patients in Hong Kong
Chan, Henry L. Y.
Tsang, Owen T. Y.
Hui, Yee Tak
Fung, James Y. Y.
Lui, Grace C. Y.
Lai, Ching Lung
Lo, Angeline O. S.
Chan, Kam Hon
But, David Y. K.
Lao, Wai Cheung
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 378 - 378
[28] 100% efficacy to ombitasvir/paritaprevir/ritonavir (± dasabuvir) with or without ribavirin in hepatitis C virus genotypes 1 and 4-infected hemodialysis patients
Sanai, F. M.
Alghamdi, A. S.
Afghani, A.
Alswat, K. A.
Aseeri, A.
Babatin, M. A.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S312 - S312
[29] Impact of hepatoprotective medications on the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir plus /- ribavirin in hepatitis C virus genotype 1b-infected Asian patients with and without cirrhosis in the ONYX-I and -II studies
Chuang, W. -L.
Luo, Y.
Heo, J.
Wang, G. -Q.
Yu, M. -L.
Kim, Y. J.
Xie, Q.
Peng, C. -Y.
Zhang, M.
Huang, Y.
Lu, W.
Fredrick, L. M.
Mobashery, N.
Wei, L.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S746 - S746
[30] Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients
Adel Abdel-Moneim
Alaa Aboud
Mohamed Abdel-Gabbar
Mohamed Zanaty
Mohamed Ramadan
Digestive Diseases and Sciences, 2018, 63 : 1341 - 1347

← 1 2 3 4 5 →